Immuron to Cooperate with Leading Australian Universities

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Immuron to Cooperate with Leading Australian Universities on Autism Research

MELBOURNE, Australia, July 20, 2016 (GLOBE NEWSWIRE) -- Australian microbiome biopharmaceutical company, Immuron Limited (ASX:IMC) (OTCQB:IMROY), today announced it has formed a strategic partnership with three leading Australian Research Institutes to understand how the genetic basis underlying Autism Spectrum Disorder (ASD) relates to changes to the gut, and how Immuron’s anti-LPS IMM-124E compound affects changes in mouse models for autism. This understanding will provide information on how alterations in the gut microbiome occur and potentially identify targets for the development of clinical therapies to restore gut balance and improve the quality of life for ASD patients.

This cutting-edge Industry / Academic collaboration is made up of a cross functional disciplinary scientific team with the capabilities to investigate the brain, the gut and the microbes, and also to translate this research into meaningful patient outcomes.  The members of the scientific team are Dr. Elisa Hill (University of Melbourne: Neuroscientist, Gut-Brain axis and Mouse models of Autism), Assoc. Prof. Ashley Franks (La Trobe University: Microbiologist, Microbial communities structures and functions) and Professor Ravi Savarirayan (Murdoch Childrens Research Institute / University of Melbourne: clinical geneticist, paediatrician and translational researcher).

Said Associate Professor Ashley Franks, Microbiologist of La Trobe University and co-principle investigator:

“ The scientific research team has recently identified that the microbiota is altered in mutant mouse models compared to their otherwise genetically identical wild type littermates. In order to determine if the fecal microbiota is a potential site for therapies in ASD, we will investigate the structure of the fecal microbiome in wild type and mutant mice, using this understanding to translate into human ASD patient studies .”

The Gastrointestinal (GI) microbiota are well known to influence mood and behaviour. There is growing evidence that gut bacterial communities (i.e. the microbiota) are altered in patients with ASD, however studies in patients have limitations due to the difficulty in controlling environmental factors.  The microbiota in the mouse GI tract is similar to that in humans and studying the microbiome in this model enables environmental factors to be controlled.

Commented Dr. Elisa Hill Neuroscientist, The University of Melbourne and co-principle investigator:

“ Research of mouse models for autism, where mutations in genes involved in the formation and remodelling of central nervous system synapses, will be extended to closely map the microbes in the gut and provide understanding on how the brain and bacteria interact during development.”

ASD is a behavioural disorder diagnosed by impaired social communication and repetitive behaviours. ASD patients often have gastrointestinal problems including bloating, constipation or diarrhoea.   Autism is a large and wide-open pharmaceutical market, with no approved therapeutics and few therapies in development.

Commented Thomas Liquard, CEO of Immuron Limited:

“With growing evidence that the microbiome might play a key role in either the development or worsening of central nervous system (CNS) conditions including autism, Immuron is pleased to partner with leaders in the field to expand the knowledge in this area and test the potential for IMM-124E as a therapeutic agent.  The data will also give us insights into the link between the microbiome and autism, allowing Immuron to design other custom therapeutics as needed.”

“Positive data would be an industry first, and the next step would be to conduct Investigator Sponsored human studies.  We have already identified a potential patient cohort and we look forward to potentially start human studies in 2017 following the results of this pre-clinical study in mice.”

About Immuron:

Immuron Ltd (ASX:IMC) (OTCQB:IMROY) is a microbiome company focused on developing and commercialising oral immunotherapeutics for the treatment of a many gut mediated diseases. Immuron has a unique and safe technology platform that enables a shorter development therapeutic cycle. The Company currently markets and sells Travelan® for the prevention of travellers’ diarrhoea, whilst its lead product candidate IMM-124E is in Phase 2b clinical trials for NASH and ASH. These products together with the Company’s other preclinical immunotherapy pipeline products targeting immune-related diseases currently under development, will meet a large unmet need in the market.

For more information visit: http://www.immuron.com/

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron’s current expectations, estimates and projections. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “guidance” and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron’s control, including those risks or uncertainties inherent in the process of both developing and commercialising technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.

Company Contact: Thomas Liquard Chief Executive Officer AUS Ph: +61 (0)3 9824 5254 thomasliquard@immuron.com Immuron US Investor Relations: Jon Cunningham RedChip Companies, Inc. US Ph: +1 (407) 644 4256, (ext. 107) jon@redchip.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Tammy Keller's Devotional Guides Living with Purpose

Updated Category News Views 97

Finding Meaning in the Dash of Life Life isn’t just bookended by birth and death; it’s the dash in between that counts. If you were sitting next to Tammy Keller right now, you’d probably hear that heartfelt truth straight from her. Her new work, "Your--Dash Devotional," rattles the soul by offering a profound look at making every moment intentional, vivid, and...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 194

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 106

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Arbor Realty Trust Hit with Securities Fraud Lawsuit

Updated Category News Views 21

Snafu at Arbor Realty: Investors Rethink Strategies You know what puts a bee in my bonnet these days? Misleading statements from companies like Arbor Realty Trust, Inc. (NYSE: ABR). The news breaks that Arbor's got itself neck-deep in a class action lawsuit, courtesy of the sharp folks over at Schall, Brown & Schwartz LLP. Now, this ain't your average financial hiccup....

Continue Reading
Québecor Makes Its Move: Eye on TELUS Amid Telecom Shakeup

Updated Category News Views 0

The Offer That Shocked the Telecom Markets Just when you think you’ve figured out the lay of the land, someone throws a curveball. Québecor’s decision to take a run at TELUS is shaking up Canada’s telecom scene big time. This isn’t just another M&A whisper; it’s a roaring freight train of a proposal valued at a whopping $31 billion. And TELUS, not just sitting...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 159

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 86

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
HONOR Leads in China, Eyes Middle East Market

Updated Category News Views 86

A Force to be Reckoned With Talk about making waves—HONOR's got the bragging rights now. Sitting pretty at the top among Android smartphone brands in China ain't no small feat. We're looking at a snazzy 12.04% market share for October 2026, all thanks to selling a cool 2.573 million units. The kicker? This ain't even their full potential. They're hustling hard in the...

Continue Reading
China's APEC Summit: A Catalyst for Business Growth?

Updated Category News Views 97

A Shift Toward Regional Stability China's position as this year's APEC rotating chair presents both opportunity and challenge as economies grapple with trade barriers and technological upheaval. The 33rd APEC Economic Leaders' Meeting in Shenzhen is intended to navigate these turbulent waters, setting the stage for a more stable regional environment. APEC's Role in...

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 133

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading

Top 5 Most Recently Viewed Articles

BexBack Launches High-Leverage Trading with Exciting Bonuses

Updated Category News Views 176

Exciting New Trading Features from BexBack BexBack, a leading cryptocurrency exchange platform, is thrilled to reveal its latest trading enhancements, designed for traders eager to amplify their market position. These innovative features are now accessible to users across the globe, marking a significant step in meeting the soaring demand for high-leverage crypto trading....

Continue Reading
BigBear.ai Partners for AI Innovation Amid Stock Surge

Updated Category News Views 208

BigBear.ai Stock Rises Dramatically BigBear.ai, Inc. (NASDAQ:BBAI) shares have experienced a substantial increase recently. This surge comes after the company announced a significant partnership aimed at enhancing its AI solutions tailored to national security needs. The latest development involves collaboration with another entity to create advanced AI-enabled hardware....

Continue Reading
Totalkredit A/S Unveils Latest Prepayment Data Insights

Updated Category News Views 289

Understanding Recent Prepayment Updates from Totalkredit A/S To all interested parties, Prepayments (CK93) In adherence to the Danish Capital Markets Act, Totalkredit A/S has made available its latest prepayment data. This release reflects the status as of May 2, 2025, and is presented in an accessible format. This information will be efficiently distributed through...

Continue Reading
Examining Coherent's Earnings Outlook and Market Trends

Updated Category News Views 126

Anticipating Coherent's Earnings Report Coherent (NYSE: COHR) is preparing to announce its quarterly earnings soon. Investors are keenly observing the financial landscape to glean insights prior to the release. Analysts predict an earnings per share (EPS) of $0.84, setting the stage for interesting discussions. Investor Expectations Optimism surrounds the forthcoming...

Continue Reading
Exciting Leadership Change at Focus Financial Partners Inc.

Updated Category News Views 319

Leadership Transition at Focus Financial Partners Focus Financial Partners Inc., a prominent player in wealth management and related financial services, has announced a significant leadership change with the appointment of Jason Dubinsky as the new Chief Financial Officer. This transition marks an important chapter for the company, with Mr. Dubinsky set to join in March....

Continue Reading